Mass General Brigham AI Project Aims to Detect 90% of Undiagnosed Early Alzheimer's Cases

A critical gap in Alzheimer's care is being targeted by AI: an estimated 90% of people in the earliest, most treatable phase of the disease currently go undiagnosed in the United States. Researchers at Mass General Brigham in Massachusetts are now deploying artificial intelligence in an attempt to identify the subtle, often unnoticed signs of Alzheimer's during this mild cognitive impairment stage. The initiative directly addresses a major bottleneck, as newer drugs that can modestly slow progression are most effective when administered early.

The project, led by Dr. Lidia Moura, director of population health in neurology at Mass General Brigham, frames early detection not as a secondary goal but as the primary frontier for improving outcomes. 'The biggest opportunity to improve Alzheimer’s care isn’t in a new drug — it’s in noticing the earliest signs sooner,' Moura stated. This shift in focus from solely drug development to enhanced diagnostic infrastructure signals a strategic pivot within neurology and population health management.

Success for this AI-driven diagnostic tool could pressure the broader healthcare system to prioritize and integrate earlier screening protocols. It places significant scrutiny on current clinical practices that allow early symptoms to be missed, raising the stakes for developing reliable, scalable detection methods. The effort underscores a growing recognition that technological intervention in the diagnostic process may be a necessary precursor to maximizing the potential of existing and future Alzheimer's therapies.